Tag Archives: Regulatorio

Pharma: Trust Deficit or the Biggest Image Problem ever faced?

  It was  Saturday afternoon; April 4th, to be precise. 7-time Tour de France winner and full-time cancer fighter: Lance Armstrong was in his born-state Texas, riding to give a speech in the PhRMA meeting in San Antonio. From his … Continue reading

Posted in Alta Dirección, Mercadotecnia, Opinión, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 3 Comments

Improving Patient Compliance, an impressive challenge and a costly task.

  By Xavier Tello One of the most important [not so] hidden costs of therapeutics and health care, is patients’ lack of adherence to treatment. According to several authors, including a review of the Cochrane Collaboration, the “desertion” index could … Continue reading

Posted in Mercadotecnia, Opinión, Planeac. Estratégica, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 5 Comments

Biogenéricos y biosimilares. Un campo aún muy confuso.

El pasado 22 de Diciembre, el Financial Times publicó una nota en la que hace referencia al deseo de AstraZeneca de incursionar en el mercado de los “bio-similares”. El Financial Times entrevista de hecho a David Brennan, CEO de AstraZeneca … Continue reading

Posted in Ciencia, Mercadotecnia, Salud, Tecnología | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment